Sangamo Therapeutics, Inc. - Common Stock (SGMO)

Sangamo Therapeutics is a biotechnology company focused on developing groundbreaking gene-editing therapies and genomic medicine to address a range of genetic diseases and disorders

By leveraging its expertise in gene modulation and genome editing technologies, including zinc finger proteins, the company aims to create innovative treatments that can permanently alter or correct genetic mutations at the DNA level. Sangamo is committed to advancing its pipeline of therapeutic candidates through rigorous research and clinical trials, collaborating with a variety of partners to expedite the development of transformative therapies for patients in need.